Review Article
Volume 9 Issue 2 - 2021
Nrf2 Related Immune Response to Tumor Development in Mice
Samera H Hamad*
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
*Corresponding Author: Samera H Hamad, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States.
Received: April 14, 2020; Published: January 30, 2021




Abstract

NRF2 has gained great attention in recent years due to its role in tumor initiation and development. NRF2 is a transcription factor that regulates more than 500 genes to protect cells from oxidative damage. Nrf2 was shown to protect against tumor initiation; however, its activation at the intermediate and the late stage of tumors has been found to support tumor growth and metastasis. This dual role depends on its activation in different cells at different stages of tumor development. This mini review discusses the activation of Nrf2 in normal, tumor and immune cells during tumor initiation and development. The focus of this mini review is on the interaction between immune cells and cancer cells through Nrf2 activation and how this might contribute to tumor initiation and metastasis. This review brings attention to several important pathways that should be considered when using NRF2 as a therapeutic target in cancer.

Keywords: Nrf2; Immune Response; Tumor Development; Mice

References

  1. Adam J., et al. “Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling”. Cancer Cell4 (2011): 524-537.
  2. Al-Huseini LM., et al. “Nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) modulates dendritic cell immune function through regulation of p38 MAPK-cAMP-responsive element binding protein/activating transcription factor 1 signaling”. Journal of Biological Chemistry 31 (2013): 22281-22288.
  3. Baldwin AS Jr. “The NF-kappa B and I kappa B proteins: new discoveries and insights”. Annual Review of Immunology 14 (1996): 649-683.
  4. Bauer AK., et al. “The involvement of NRF2 in lung cancer”. Oxidative Medicine and Cellular Longevity (2013): 746432.
  5. Beury DW., et al. “Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2”. Journal of Immunology8 (2016): 3470-3478.
  6. Bolisetty S., et al. “Macrophage and epithelial cell H-ferritin expression regulates renal inflammation”. Kidney International 1 (2015): 95-108.
  7. Boss AP., et al. “The Nrf2 activator tBHQ inhibits the activation of primary murine natural killer cells”. Food and Chemical Toxicology 121 (2018): 231-236.
  8. Burnet FM. “The concept of immunological surveillance”. Progress in Experimental Tumor Research 13 (1970): 1-27.
  9. Cuadrado A., et al. “Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach”. Pharmacological Reviews 2 (2018): 348-383.
  10. DeNicola GM., et al. “Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis”. Nature7354 (2011): 106-109.
  11. Dunn GP., et al. “Cancer immunoediting: from immunosurveillance to tumor escape”. Nature Immunology 3 (2002): 991-998.
  12. Dunn GP., et al. “A critical function for type I interferons in cancer immunoediting”. Nature Immunology7 (2005): 722-729.
  13. Feng R., et al. “Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction”. Cell Communication and Signaling: CCS1 (2018): 54.
  14. Fidler IJ. “The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited”. Nature Reviews Cancer 6 (2003): 453-458.
  15. Gabrilovich DI and Nagaraj S. “Myeloid-derived suppressor cells as regulators of the immune system”. Nature Reviews Immunology3 (2009): 162-174.
  16. Hayes JD., et al. “Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway”. Antioxidants and Redox Signaling 11 (2010): 1713-1748.
  17. Hu R., et al. “Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with anti-inflammatory”. Antioxidants and Redox Signaling 11 (2010): 1679-1698.
  18. Kensler TW and Wakabayashi N. “Nrf2: friend or foe for chemoprevention?” Carcinogenesis1 (2010): 90-99.
  19. Khansari N., et al. “Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer”. Recent Patents on Inflammation and Allergy Drug Discovery1 (2009): 73-80.
  20. Kobayashi EH., et al. “Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription”. Nature Communications 7 (2016): 11624.
  21. Koebel CM., et al. “Adaptive immunity maintains occult cancer in an equilibrium state”. Nature 7171 (2007): 903-907.
  22. Kogure A., et al. “Cross-talk between cancer cells and their neighbors via miRNA in extracellular vesicles: an emerging player in cancer metastasis”. Journal of Biomedical Science 1 (2019): 7.
  23. Kumar P., et al. “IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection”. Scientific Reports 9 (2019): 4984.
  24. Ma Q and He X. “Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2”. Pharmacological Reviews4 (2012): 1055-1081.
  25. Man YG., et al. “Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories”. Journal of Cancer 4 (2013): 84-95.
  26. Murdoch C., et al. “The role of myeloid cells in the promotion of tumour angiogenesis”. Nature Reviews Cancer 8 (2008): 618-631.
  27. Noel S., et al. “T Lymphocyte-Specific Activation of Nrf2 Protects from AKI”. Journal of the American Society of Nephrology: JASN12 (2015): 2989-3000.
  28. O'Sullivan T., et al. “Interleukin-17D mediates tumor rejection through recruitment of natural killer cells”. Cell Reports4 (2014): 989-998.
  29. Pyaram K., et al. “Keap1-Nrf2 System Plays an Important Role in Invariant Natural Killer T Cell Development and Homeostasis”. Cell Reports3 (2019): 699-707.e694.
  30. Saddawi-Konefka R., et al. “Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance”. Cell Reports9 (2016): 2348-2358.
  31. Sakurai H., et al. “Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway”. Journal of Biological Chemistry 38 (2003): 36916-36923.
  32. Satoh H., et al. “Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung”. Carcinogenesis 10 (2010): 1833-1843.
  33. Shankaran V., et al. “IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity”. Nature 6832 (2001): 1107-1111.
  34. Smale ST. “Hierarchies of NF-kappaB target-gene regulation”. Nature Immunology8 (2011): 689-694.
  35. Sporn MB and Liby KT. “NRF2 and cancer: the good, the bad and the importance of context”. Nature Reviews Cancer 8 (2012): 564-571.
  36. Suzuki T., et al. “Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice”. Molecular and Cellular Biology 15 (2017): e00063.
  37. Taguchi K., et al. “Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution”. Genes to Cells: Devoted to Molecular and Cellular Mechanisms2 (2011): 123-140.
  38. Terabe M and Berzofsky JA. “The role of NKT cells in tumor immunity”. Advances in Cancer Research 101 (2008): 277-348.
  39. Thimmulappa RK., et al. “Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis”. Journal of Clinical Investigation 4 (2006): 984-995.
  40. Yu H., et al. “Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment”. Nature Reviews Immunology1 (2007): 41-51.
  41. Zhang D., et al. “Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice”. Antioxidants and Redox Signaling 16 (2018): 1535-1552.
  42. Zhang P., et al. “Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth”. Molecular Cancer Therapeutics2 (2010): 336-346.
Citation: Samera H Hamad. “Nrf2 Related Immune Response to Tumor Development in Mice”. EC Pharmacology and Toxicology 9.2 (2021): 16-21.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk